The mRNA therapeutics field is rapidly evolving beyond vaccines to include treatments for cancer, genetic disorders and in vivo cell therapies, bringing with it diverse production challenges. As the ...

Advancements in manufacturing technologies is a key driver driving nucleic acid therapeutics CDMO market revenue growth.

Monkeypox Vaccine and Treatment revenue is expected to grow at a CAGR of 10.20% from 2025 to 2032, reaching nearly USD 225.12 Mn by 2032.

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and formulation capabilities with the launch of a GMP-like mRNA manufacturing ...

Acuitas’ LNP enabled delivery of three doses of a personalized CRISPR therapy with no adverse events to an infant patient with urea cycle disorder ...

Broad liver distribution and slightly delayed mRNA expression in human hepatocytes were observed, reinforcing the model’s value in studying human-specific responses to LNP-based therapies.

In contrast, polyethylene glycol (PEG)-lipid standards, commonly used in current LNP formulations, elicited a strong and boosted antibody response. Anti-PEG antibodies have been implicated as a ...

Lipid nanoparticles (LNPs) are an effective delivery system for gene therapeutics. By optimizing their formulation, the physiochemical properties of LNPs can be tailored to improve tissue penetration, ...

With easy-to-follow instructions included, users can fine tune the LNP formulation process to achieve the production of nanoparticles with the desired physicochemical characteristics, such as PDI ≤0.2 ...

It possesses strong capability of novel Cas and base editor discovery and exceptional in-house LNP production capacity for GMP manufactory, with independent intellectual property rights and core ...

5.3 mRNA-LNP synthesis for mRNA vaccine designing For mRNA-LNP synthesis, different lipids and mRNA are usually dissolved in the ethanol and acidic aqueous phases (such as pH 4.0 citrate buffer) with ...

Together with the company’s cGMP-ready infrastructure and process for clinical dose production, these platforms collectively form the foundation of PopVax’s ability to rapidly take new mRNA ...